This report combines human measurements with laboratory intervention experiments. Keeping those evidence layers separate is essential to understanding its relevance. Primary study
What was studied
Plasma GHK was lower in nine people with COPD than in eleven controls. Separately, GHK-Cu improved selected muscle, strength, and oxidative-stress measures in smoke-exposed mice and cultured muscle cells. SIRT1 involvement was investigated using activity assays, computational docking, and an inhibitor that weakened protective effects. The human participants did not constitute a GHK-Cu treatment trial. Primary report
Our appraisal: triangulation does not erase design boundaries
Combining several experimental approaches can make a hypothesis more coherent. It does not convert an observational human comparison into evidence of human treatment benefit. Lower concentrations in disease could be a cause, consequence, or correlate of other changes.
Mechanistic evidence also comes in different forms. A docking calculation predicts a possible molecular interaction. An enzyme-activity assay measures a functional response. An inhibitor experiment asks whether disrupting a pathway changes that response. None should be casually renamed a direct physical binding measurement.
An inhibitor result is informative, but interpretation depends on its specificity and on the effects of the inhibitor itself. Additional approaches can strengthen a mechanism without being interchangeable with the original experiment. A claim that a pathway is involved is generally narrower than a claim that it is the only target.
The muscle endpoints require similar discipline. Preserving mass, improving grip strength, and changing molecular markers are related observations, not a complete demonstration of restored exercise capacity in patients. A smoke-exposure model also does not represent every cause of muscle wasting.
The appropriate conclusion is a translational hypothesis supported by preclinical experiments and a small human association. It is not evidence that GHK-Cu treats COPD-related weakness in people or offsets the health risks of smoking.
Frequently asked questions
Were people given GHK-Cu in this study?
Not in the reported human comparison.
What was measured in people?
Circulating GHK and related clinical measures.
Where were interventions tested?
In cells and mice.
Which pathway was investigated?
SIRT1-associated signaling.
Does docking establish physical binding?
Not by itself.
Does this support smoking-risk protection in humans?
No.
What evidence is still needed?
Appropriate clinical intervention studies and stronger mechanistic validation.